Education
About Us
Working with TipRanks
Follow Us
IGC Pharma (DE:IGS1)
FRANKFURT:IGS1
IGS1 Stock Chart & Stats
€0.28
<€0.01(0.63%)
At close: 4:00 PM EST
€0.28
<€0.01(0.63%)
Day’s Range― - ―
52-Week Range€0.21 - €0.53
Previous CloseN/A
Volume0.00
Average Volume (3M)1.02K
Market Cap
€23.68M
Enterprise Value€25.61M
Total Cash (Recent Filing)€1.10M
Total Debt (Recent Filing)€137.00K
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Jun 15, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding95,818,020
10 Day Avg. Volume936
30 Day Avg. Volume1,023
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.45
Price to Sales (P/S)17.16
P/FCF Ratio-4.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.33Price Target Upside1445.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)€890.31K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilitySale of the manufacturing facility with secured long‑term preferential supply rights strengthens liquidity and supply assurances, improving financial stability during clinical development.
Clinical EfficacyInterim Phase 2 trial data showed a clear and statistically significant reduction in agitation versus placebo in Alzheimer’s patients, supporting the therapy's potential clinical benefit.
Development MilestonesProgress toward completing the CALMA Phase 2 trial and launching an AI beta program provides defined milestones that could attract investor attention as development advances.
Bears Say
Clinical Trial RiskSignificant development and clinical trial risks mean failed or inconclusive studies could sharply reduce the company's valuation and investor confidence.
Concentration Of ProgramsHeavy reliance on a small number of Alzheimer’s drug candidates creates binary outcomes where setbacks in key programs could disproportionately impact the stock.
Revenue And Financing RiskAs a clinical‑stage company with minimal revenue, additional funding needs could strain the balance sheet and lead to shareholder dilution if capital must be raised.
IGC Pharma News
IGS1 FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was €0.21 and its highest was €0.53 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is €23.68M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Jun 15, 2026 which is in 90 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Feb 18, 2026. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 95,818,020 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in DE:IGS1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
IGS1 Earnings Call
Q2 2025
0:00 / 0:00
IGS1 Stock 12 Month Forecast
Average Price Target
€4.33
▲(1445.72% Upside)
Technical Analysis
Options Prices
Currently, No data available
---